Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Metadata
Title
Complete response of a primary cutaneous T-cell-rich B cell lymphoma treated with interferon α2a
Author
U. Wollina
Publication date
01-03-1998
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 2/1998
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s004320050144

Other articles of this Issue 2/1998

Journal of Cancer Research and Clinical Oncology 2/1998 Go to the issue

ORIGINAL PAPER

Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?

OriginalPaper

Erratum: J Cancer Res Clin Oncol (1997) 123: 595—601

ORIGINAL PAPER

Differentiation, proliferation and apoptosis levels in human leiomyoma and leiomyosarcoma

ORIGINAL PAPER

Impaired granulocytic function in patients with acute leukaemia: only partial normalisation after successful remission-inducing treatment

ORIGINAL PAPER

Expression of membrane-type matrix metalloproteinase-1 in human pancreatic adenocarcinomas

ORIGINAL PAPER

Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits